Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aggressive Treatment of Heart Patients with Cholesterol-lowering Medication

01.09.2004


Treating heart-attack patients earlier with a more aggressive regimen of cholesterol-lowering medicines may help diminish their chances of sustaining more complications later or dying after their heart attack, researchers at UT Southwestern Medical Center at Dallas have found.



The findings, published online today by The Journal of the American Medical Association, show benefits of treating patients who have recently suffered acute coronary syndromes with higher doses of the cholesterol-lowering drugs called statins soon after they experience heart-attack symptoms.

Dr. James de Lemos, assistant professor of internal medicine at UT Southwestern, is lead author of the second of a two-part, collaborative international study called the Aggrastat to Zocor study, or A to Z study. Dr. Michael Blazing of the Duke Clinical Research Institute presented the study Aug. 30 at the European Society of Cardiology meeting in Munich, Germany.


The primary objective of the first phase or the “A” phase was to assess the safety and effectiveness of two different forms of clot-preventing drugs – enoxaparin and unfractionated heparin – in treatment following heart attacks.

The second, or “Z” phase, evaluated two different strategies of treating patients with cholesterol-lowering medicines.

In the past, Dr. de Lemos said, heart-attack patients were stabilized for several weeks or months and placed on low-cholesterol diets before physicians intervened with statin drugs. “Earlier medical protocols called for patients to receive lower dosages of statins later following a heart attack,” said Dr. de Lemos, an investigator in the Donald W. Reynolds Cardiovascular Clinical Research Center at UT Southwestern. “We observed trends that suggested an earlier, more intensive cholesterol-lowering regimen was better than a delayed, less-aggressive regimen.”

The trial – which enrolled patients between December 1999 and January 2003 – followed 4,500 patients at 322 medical facilities spanning 41 different countries. Half of the trial participants received higher dosages of statin drugs soon after a heart attack. The second group was given lower dosages of the same medicines after a longer recovery time following a heart attack.

Patients given statin drugs earlier showed modest improvement in the rate of subsequent death, congestive heart failure, heart attack and stroke compared with patients who received a later start of a lower-dose statin regimen.

According to the study, 14.4 percent of patients in the group that got higher dosages of statins soon after a heart attack suffered other cardiac events such as heart attacks and strokes compared to 16.7 percent of patients receiving later intervention with lower dosages of the cholesterol-lowering drugs.

“Until recently, little information was available about the timing of initiating statin drugs after a heart attack,” Dr. de Lemos said. “The findings from the A to Z trial suggest that statins can be initiated earlier and in dosages well above the typical starting dose.”

Dr. de Lemos also warned that statin drugs must be closely monitored and the dose decreased or discontinued if side effects such as muscle weakness occur. Muscle pain and weakness (myopathy) is an important side effect of statin drugs and was observed in 0.4 percent of patients receiving the highest dose of simvastatin.

Other investigators included Dr. Eugene Braunwald of Brigham and Women’s Hospital in Boston, the paper’s senior author; researchers from Duke Clinical Research Institute; the University of Edinburgh in Scotland; Green Lane Hospital in Aukland, New Zealand; the University of Montreal and Aker Hospital in Oslo, Norway.

The study was supported by a grant from Merck & Co.

| newswise
Further information:
http://www.utsouthwestern.edu

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

Meter-sized single-crystal graphene growth becomes possible

22.08.2017 | Materials Sciences

Repairing damaged hearts with self-healing heart cells

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>